The pharmaceutical firm's Lilly Asia Ventures unit is co-investing in the T-cell technology developer with University of Pennsylvania.
Tmunity Therapeutics, a US-based developer of T cell-based treatments for a wide range of diseases, is raising $10m from investors including Lilly Asia Ventures, a subsidiary of pharmaceutical company Eli Lilly.
Penn Medicine, the academic medical centre of University of Pennsylvania, is also taking part in the equity financing, the first to be raised by Tmunity.
Tmunity was founded by faculty and researchers from Penn’s Center for Cellular Immunotherapies, and its prospective drugs are based on research conducted there. It…
